Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer
Small Cell Lung Cancer
About this trial
This is an interventional treatment trial for Small Cell Lung Cancer
Eligibility Criteria
Inclusion Criteria: Histological or cytological proof of neuroendocrine cancers (including small cell cancers of any site [including lung] or poorly differentiated neuroendocrine cancers of the lung with (unidimensionally) measurable disease as per the RECIST criteria Chemoresistant or chemosensitive disease Patients must have received treatment with at least one but not more than 2 prior chemotherapy regimens, including one regimen containing a platinum agent Radiation therapy must have completed their radiation at least 14 days prior to being registered for protocol therapy, and toxicities due to radiation must have recovered to < grade 1 or baseline prior to registration Negative pregnancy test Exclusion Criteria: No clinically significant infections as judged by the treating investigator No symptomatic CNS metastasis No radiation to > 25% of the marrow containing spaces No previous treatment with pemetrexed No uncontrolled pleural effusions No current breastfeeding
Sites / Locations
- Helen F. Graham Cancer Center
- Medical & Surgical Specialists, LLC
- Elkhart Clinic
- Oncology Hematology Associates of SW Indiana
- Fort Wayne Oncology & Hematology, Inc
- Center for Cancer Care at Goshen Health System
- Indiana University Cancer Center
- Community Regional Cancer Center
- Arnett Cancer Care
- Medical Consultants, P.C.
- Center for Cancer Care, Inc., P.C.
- Northern Indiana Cancer Research Consortium
- Northern Indiana Oncology Associates
- AP&S Clinic
- Siteman Cancer Center
- Methodist Cancer Center
Arms of the Study
Arm 1
Active Comparator
1
Pemetrexed for patients with chemosensitive and chemoresistant relapsed small cell lung cancer.